Off-patent oral solids and complex generics (inhalers, long-acting, peptides) made in USFDA-approved plants and sold into the US, Europe and emerging markets.
Dr Reddy's LaboratoriesDirect supplier · HighListed
Aurobindo PharmaDirect supplier · HighListed
LupinDirect supplier · HighListed
Zydus LifesciencesDirect supplier · HighListed
CiplaDirect supplier · HighListed
Sun Pharmaceutical IndustriesDirect supplier · MediumListed
Files ANDAs, challenges patents (Para IV) and manufactures generic tablets, capsules and complex dosage forms at scale in USFDA-inspected plants, selling to US wholesalers and pharmacy chains and to European and emerging-market buyers.
Why it matters
India supplies roughly four in ten generic prescriptions filled in the US, and the US is about a third of India's ~US$30bn pharma exports. US generics earnings drive sentiment for the large caps - and are now exposed to two shocks at once: the gRevlimid exclusivity tail ended in Jan 2026, and the US has set a generic-tariff timeline (0% to Jul 2028, 100% then 200%) for companies that do not build US capacity.
Where the value pool sits
Plain oral-solid generics face 5-10% annual US price erosion and are low-margin; profit concentrates in limited-competition products - first-to-file 180-day exclusivities, complex generics (inhalers, injectables, peptides like gLiraglutide/gSemaglutide) and drug-shortage opportunities. When one big product ages out (gRevlimid, gSpiriva, gMyrbetriq), earnings can drop sharply.
Key drivers
Complex-generic and first-to-file launch pipeline
US drug shortages favouring reliable Indian suppliers
GLP-1 / semaglutide patent expiries in Canada, Brazil, India and other markets from 2026
Emerging-market and European expansion to diversify from the US
Potential bottlenecks
USFDA facility status gates approvals: an OAI or warning letter freezes new launches from that plant
Consolidated US buyers (three purchasing groups buy most generics) hold pricing power
Complex generics need device, clinical-endpoint and bioequivalence capabilities few companies have
Investor metrics to watch
US revenue (US$m) per quarter and growth ex-big-product
Number of pending ANDAs / first-to-file opportunities
USFDA status of key sites (VAI / OAI / WL / import alert)